<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005940</url>
  </required_header>
  <id_info>
    <org_study_id>1470.00</org_study_id>
    <secondary_id>NCI-2013-01361</secondary_id>
    <secondary_id>FHCRC-1470.00</secondary_id>
    <secondary_id>NCI-H00-0056</secondary_id>
    <secondary_id>1470</secondary_id>
    <secondary_id>CDR0000067778</secondary_id>
    <secondary_id>1470.00</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>P01CA044991</secondary_id>
    <nct_id>NCT00005940</nct_id>
  </id_info>
  <brief_title>Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission</brief_title>
  <official_title>Phase II Study of Radiolabeled BC8 (Anti-CD45) Antibody Combined With Busulfan and Cyclophosphamide as Treatment for Acute Myelogenous Leukemia in First Remission Followed by HLA-Identical Related Peripheral Blood Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well iodine I 131 monoclonal antibody BC8, busulfan, and
      cyclophosphamide followed by donor stem cell transplant works in treating patients with acute
      myeloid leukemia that has decreased or disappeared, but the cancer may still be in the body.
      Giving chemotherapy drugs, such as busulfan and cyclophosphamide before a donor peripheral
      blood stem cell transplant helps stop the growth of cancer or abnormal cells and helps stop
      the patient's immune system from rejecting the donor's stem cells. Also, radiolabeled
      monoclonal antibodies, such as iodine I 131 monoclonal antibody BC8, can find cancer cells
      and carry cancer-killing substances to them without harming normal cells. When the stem cells
      from a related donor, that closely matches the patient's blood, are infused into the patient
      they may help the patient's bone marrow make stem cells, red blood cells, white blood cells,
      and platelets.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the efficacy (as measured by survival and disease-free survival) and toxicity
      of a regimen of busulfan 16 mg/kg and cyclophosphamide 120 mg/kg plus 131I-labeled
      anti-cluster of differentiation (CD) 45 antibody (iodine I 131 monoclonal antibody BC8)
      (delivering a dose of 5.25 gray [Gy] to the normal organ receiving the highest dose) in
      patients with acute myeloid leukemia (AML) in first remission receiving human leukocyte
      antigen (HLA)-identical related peripheral blood stem cell (PBSC) transplants.

      OUTLINE:

      RADIOLABELED ANTIBODY: Patients receive iodine I 131 monoclonal antibody BC8 intravenously
      (IV) on day -13.

      CHEMOTHERAPY: Patients receive busulfan orally (PO) every 6 hours on days -7 to -4 and
      cyclophosphamide IV on days -3 and -2.

      TRANSPLANT: Patients undergo allogeneic PBSC or bone marrow (BM) transplant on day 0.

      GRAFT-VS-HOST DISEASE PREVENTION: Patients receive cyclosporine IV or PO every 12 hours on
      days -1 to 50 with a taper to day 180. Patients also receive methotrexate IV on days 1, 3, 6,
      and 11.

      After completion of study treatment, patients are followed up at 6, 9, and 12 months; every 6
      months for 1 year; and then yearly thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1999</start_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Summarized using appropriate time-to-event methods with estimates of the corresponding confidence intervals provided.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Summarized using appropriate time-to-event methods with estimates of the corresponding confidence intervals provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse of AML patients</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Summarized using appropriate time-to-event methods with estimates of the corresponding confidence intervals provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant-related mortality</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Transplant-related toxicities are graded using the National Cancer Institute (NCI) Common Toxicity Criteria (CTC) version 2. Summarized using appropriate time-to-event methods with estimates of the corresponding confidence intervals provided.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Adult Acute Myeloid Leukemia in Remission</condition>
  <condition>Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities</condition>
  <condition>Adult Acute Myeloid Leukemia With Del(5q)</condition>
  <condition>Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)</condition>
  <arm_group>
    <arm_group_label>Treatment (radiolabeled BC8, chemotherapy, PBSCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RADIOLABELED ANTIBODY: Patients receive iodine I 131 monoclonal antibody BC8 IV on day -13.
CHEMOTHERAPY: Patients receive busulfan PO every 6 hours on days -7 to -4 and cyclophosphamide IV on days -3 and -2.
TRANSPLANT: Patients undergo allogeneic PBSC or BM transplant on day 0.
GRAFT-VS-HOST DISEASE PREVENTION: Patients receive cyclosporine IV or PO every 12 hours on days -1 to 50 with a taper to day 180. Patients also receive methotrexate IV on days 1, 3, 6, and 11.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>iodine I 131 monoclonal antibody BC8</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (radiolabeled BC8, chemotherapy, PBSCT)</arm_group_label>
    <other_name>I 131 MOAB BC8</other_name>
    <other_name>I 131 Monoclonal Antibody BC8</other_name>
    <other_name>iodine I 131 MOAB BC8</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (radiolabeled BC8, chemotherapy, PBSCT)</arm_group_label>
    <other_name>BSF</other_name>
    <other_name>BU</other_name>
    <other_name>Misulfan</other_name>
    <other_name>Mitosan</other_name>
    <other_name>Myeloleukon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (radiolabeled BC8, chemotherapy, PBSCT)</arm_group_label>
    <other_name>CPM</other_name>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Endoxana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
    <description>Undergo allogeneic PBSC or bone marrow transplant</description>
    <arm_group_label>Treatment (radiolabeled BC8, chemotherapy, PBSCT)</arm_group_label>
    <other_name>bone marrow therapy, allogeneic</other_name>
    <other_name>bone marrow therapy, allogenic</other_name>
    <other_name>transplantation, allogeneic bone marrow</other_name>
    <other_name>transplantation, allogenic bone marrow</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>Undergo allogeneic PBSC or bone marrow transplant</description>
    <arm_group_label>Treatment (radiolabeled BC8, chemotherapy, PBSCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>Undergo allogeneic PBSC or bone marrow transplant</description>
    <arm_group_label>Treatment (radiolabeled BC8, chemotherapy, PBSCT)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSC transplantation</other_name>
    <other_name>peripheral blood progenitor cell transplantation</other_name>
    <other_name>transplantation, peripheral blood stem cell</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Treatment (radiolabeled BC8, chemotherapy, PBSCT)</arm_group_label>
    <other_name>ciclosporin</other_name>
    <other_name>cyclosporin</other_name>
    <other_name>cyclosporin A</other_name>
    <other_name>CYSP</other_name>
    <other_name>Sandimmune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (radiolabeled BC8, chemotherapy, PBSCT)</arm_group_label>
    <other_name>amethopterin</other_name>
    <other_name>Folex</other_name>
    <other_name>methylaminopterin</other_name>
    <other_name>Mexate</other_name>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (radiolabeled BC8, chemotherapy, PBSCT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with AML in first remission

          -  Creatinine &lt; 2.0 mg/dl

          -  Bilirubin &lt; 1.5 mg/dl which is expected to exclude patients at high risk of developing
             veno-occlusive disease of the liver

          -  Aspartate aminotransferase (AST) &lt; 1.5 times the upper limit of normal which is
             expected to exclude patients at high risk of developing veno-occlusive disease of the
             liver

          -  Patients must have an expected survival of &gt; 60 days and must be free of major
             infection

          -  DONOR: genotypic or phenotypic HLA-matched family members; related donors should be
             matched by molecular methods at the intermediate resolution level at HLA-A, B, C, and
             DR beta 1 (DRB1) according to Fred Hutchinson Cancer Research Center (FHCRC) Standard
             Practice Guidelines and to the allele level at DQ beta 1 (DQB1)

        Exclusion Criteria:

          -  Patients with history of or current leukemic involvement of the central nervous system
             (CNS)

          -  Prior radiation to maximally tolerated levels to any normal organ

          -  Inability to understand or give an informed consent

          -  Patients who are seropositive for human immunodeficiency virus (HIV)

          -  Perceived inability to tolerate diagnostic or therapeutic procedures, particularly
             treatment in radiation isolation

          -  Circulating antibody against mouse immunoglobulin

          -  DONOR: unrelated donors and donors mismatched for 1 or more HLA antigens

          -  DONOR: donors who for psychologic, physiologic or medical reasons are unable to
             undergo filgrastim (G-CSF)- mobilized PBSC collection or marrow harvesting

          -  DONOR: donors who are seropositive for HIV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnnie Orozco</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pacific Northwest National Laboratory</name>
      <address>
        <city>Richland</city>
        <state>Washington</state>
        <zip>99352</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>July 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2003</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Iodine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

